Researchers will launch a randomized clinical trial to assess whether PGx-guided care helps keep patients out of the ER and ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

The firm will offer up to 12,030,218 common shares for Keystone Capital Partners to sell and is expecting to net around $2.1 million in gross proceeds.

The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.

The foundation hopes to put the funds toward two clinical programs in blood cancers and one preclinical project in solid tumors.

In the deal, GenomOncology will integrate Pillar's RUO NGS panels into its clinical decision support platform to enable personalized cancer treatment insights.

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...